Psylo, a preclinical-stage biotechnology company, has raised USD 8 million in a seed funding round led by Tenmile, with participation from Palo Santo, Focalpoint Ventures, Mystic Ventures, and Gaingels.
The new funds raised will be used to speed up the progress of Psylo's PSYLO-100X, a non-hallucinogenic 5-HT2A agonist, which aims to treat depression and other mental health disorders.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.